This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Prague: Battleground In The Fight Against Retinal Diseases

LUGANO, Switzerland, November 2, 2012 /PRNewswire/ --

12 th   International AMD and Retina Congress in Prague, 2-3 Nov 2012

ESASO, the European School for Advanced Studies in Ophthalmology, has opened the 12th AMD and Retina Congress in  Prague . Following on from the 11th congress in Lisbon, which covered the whole spectrum of ret i nopathy, t his  year's  meeting in the Czech Republic takes a significant step forward, demonstrating how international collaboration and e x change among ophthalmologists can facilitate therapeutic advancements. ESASO expects around 1000 delegates from 40 countries. Twenty-three plenary presentations are planned with 20 case studies, six meet-the-expert-sessions as well as panel discussions and a poster exhibition.

The first session, will be chaired by Prof. Anat Loewenstein from the Tel Aviv Medical Center and Prof. Frank Holz from the University of Bonn, who will review therapeutic approaches to the treatment of retinal vein occlusion (RVO). In particular, this session will discuss the evidence for intravitreous aflibercept which has the potential to offer new treatment options for patients with RVO.

A second session focuses on surgical treatment of macular diseases and will be chaired by Prof. Anselm Kampik from the Ludwig Maximillians University in Munich and Michael Georgopoulos from the Medical University of Vienna and the Vienna Medical Hospital.  During this session, the Faculty will discuss the role of surgical treatments in the management of patients with diabetic macular edema (DME). An additional focus will be the challenges and impact of cataract surgery in patients with AMD and diabetic retinopathy.

Expanding the role of anti-VEGF therapy in ocular disease: examining the evidence, is the title of the session to be led by Prof. Leonidas Zografos, Chairman at the Faculty of Biology and Medicine of the University of Lausanne and Prof. Gabriel Coscas from the Créteil University Eye Clinic at the University of Paris XII. The session will cover a controversial issue: the role of anti-VEGF therapy in the field of ocular tumours.

With 366 million people worldwide predicted to have diabetes by 2030, the treatment of diabetic retinopathy is a key clinical challenge, and will be the subject of the session chaired by Prof. Paul Michell from the University of Sydney and Dr. Susan B. Bressler from the Johns Hopkins University School of Medicine in Baltimore. Leading retina specialists will discuss a new system for the classification of DME. This system facilitates innovative treatment paradigms that minimise the risk of moderate visual loss, including the approval of the anti-VEGF agent ranibizumab. In a roundtable discussion a faculty of experts will address a variety of topics on the management of DME, ranging from the role of wide-field angiography and OCT, to systemic management.

A further session is devoted to the management of neovascular AMD; Prof. Ursula Schmidt-Erfurth from the University of Vienna and Marco Zarbin from the New Jersey Medical School in Newark NJ, USA will Chair this session and 12 specialists will present various interactive clinical cases including recalcitrant vascularized PED, and the treatment of PCV in the anti-VEGF era.

In the final session, two scientists from the Oakland University in Royal Oak, MI, USA, Prof. Antonio Capone Jr., Clinical Professor of Biomedical Sciences and Dr. George Williams, Chair of the department of Ophthalmology will lead a session highlighting the disorders of the vitreomacular interface. One of the topics in this session will be to explore whether pharmacological vitreolysis has the potential to induce total posterior vitreous detachment without the need for surgery.  

Beside this engaging scientific programme, the humanitarian award, XOVA, will be an integral part of the congress. XOVA is an award program led by international eye care specialists and sponsored by Novartis Pharma and Alcon. XOVA provides funding (in the form of a grant) to non-profit initiatives that are expected to have a significant impact on unmet needs in ophthalmology. The 2012 XOVA award will be presented during the congress.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,172.68 -107.06 -0.62%
S&P 500 1,994.29 -16.11 -0.80%
NASDAQ 4,527.6890 -52.10 -1.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs